interferon beta-1a

This medicine is authorised for use in the European Union.


Avonex is a medicine used to treat:

  • patients with relapsing multiple sclerosis (MS). MS is a disease in which inflammation damages the protective insulation around nerves (demyelination) as well as the nerves themselves. In relapsing MS, the patient has attacks (relapses) between periods with no symptoms. Avonex slows the progression of disability and reduces the number of relapses;
  • patients who have had a single attack of demyelination, when this is severe enough to need treatment with injectable corticosteroids (anti‑inflammatory medicines). It is used when the patient is considered to be at high risk of developing MS. Before using Avonex, doctors need to exclude other causes for the symptoms.

Avonex contains the active substance interferon beta-1a.

This EPAR was last updated on 18/01/2023

Authorisation details

Product details
Agency product number
Active substance
interferon beta-1a
International non-proprietary name (INN) or common name
interferon beta-1a
Therapeutic area (MeSH)
Multiple Sclerosis
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Biogen Netherlands B.V. 
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Biogen Netherlands B.V.
Prins Mauritslaan 13
1171 LP Badhoevedorp
The Netherlands

Product information

10/08/2023 Avonex - EMEA/H/C/000102 - IA/0196/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

Avonex is indicated for the treatment of:

  • patients diagnosed with relapsing multiple sclerosis (MS). In clinical trials, this was characterised by two or more acute exacerbations (relapses) in the previous three years without evidence of continuous progression between relapses; Avonex slows the progression of disability and decreases the frequency of relapses;
  • patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite MS.

Avonex should be discontinued in patients who develop progressive MS.

Assessment history

How useful was this page?

Add your rating
5 ratings
1 rating